NCT00144573
Completed
Not Applicable
An Open-Label, Clinical Pharmacology Study to Evaluate the Safety and PK of MRA in Patients With RA With Renal Impairment
ConditionsRheumatoid Arthritis
DrugsMRA(Tocilizumab)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Rheumatoid Arthritis
- Sponsor
- Chugai Pharmaceutical
- Enrollment
- 14
- Primary Endpoint
- 20% improvement based on the ACR criteria compared with the baseline value.
- Status
- Completed
- Last Updated
- 17 years ago
Overview
Brief Summary
This is an open-label, clinical pharmacology study to evaluate the safety and PK of MRA in patients with RA with Renal Impairment.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
20% improvement based on the ACR criteria compared with the baseline value.
Time Frame: throughout study
Secondary Outcomes
- Time courses taken from baseline values for DAS28, for ACR20%, 50%, and 70% improvement, and for each ACR core set variable.(Week 0, Week 4)
Similar Trials
Completed
Phase 3
Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA)Systemic Juvenile Idiopathic ArthritisNCT00144664Chugai Pharmaceutical19
Completed
Phase 1
A Study to Assess the Potential for Pre-systemic Inhibition of CYP3A by Idebenone Using Midazolam as a SubstrateDrug-Drug InteractionNCT02887443Santhera Pharmaceuticals32
Completed
Phase 3
Phase III Comparative Study(Open-Label) of MRA for Rheumatoid Arthritis(RA)Rheumatoid ArthritisNCT00144508Chugai Pharmaceutical306
Completed
Phase 3
PhaseⅢOpen-label Study of MRA for Rheumatoid Arthritis(RA)Rheumatoid ArthritisNCT00380601Chugai Pharmaceutical20
Completed
Not Applicable
Drug-Drug Interaction Study of MRA in Patient With Rheumatoid Arthritis (RA)Rheumatoid ArthritisNCT00144560Chugai Pharmaceutical31